https://orcid.org/0009-0005-0118-7596
References
- Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis – the Canadian perspective. J Pain Res. 2016;9:735–744. doi:10.2147/JPR.S98182
- Legislative Services Branch. Consolidated federal laws of Canada, Cannabis Act; October 17, 2020. Available from: https://laws-lois.justice.gc.ca/eng/acts/c-24.5/fulltext.html. Accessed October 5, 2022.
- Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474–2483. doi:10.1001/jama.2015.6199
- An Action Plan for Pain in Canada. Health Canada; 2021. Available from: https://www.canada.ca/content/dam/hc-sc/documents/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2021-rapport/report-rapport-2021-eng.pdf. Accessed December 17, 2022.
- Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. CMAJ Open. 2021;9(2):E342. doi:10.9778/cmajo.20200187
- St.Pierre M, Matthews L, Walsh Z. Cannabis education needs assessment among Canadian physicians-in-training. Complement Ther Med. 2020;49:102328. doi:10.1016/j.ctim.2020.102328
- Zeng L, Lytvyn L, Wang X, et al. Values and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review. BMJ Open. 2021;11(9):e050831. doi:10.1136/bmjopen-2021-050831
- Cahill SP, Lunn SE, Diaz P, Page JE. Evaluation of patient reported safety and efficacy of Cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9:626853. doi:10.3389/fpubh.2021.626853
- Mangual-Pérez D, Tresgallo-Parés R, Ramírez-González M, et al. Patient experience and perspective on medical Cannabis as an alternative for musculoskeletal pain management. JAAOS Glob Res Rev. 2022;6(7). doi:10.5435/JAAOSGlobal-D-22-00055
- Piper BJ, Beals ML, Abess AT, et al. Chronic pain patients’ perspectives of medical cannabis. Pain. 2017;158(7):1373–1379. doi:10.1097/j.pain.0000000000000899
- Health Canada. Cannabis for medical purposes under the Cannabis Act: information and improvements; May 20, 2022. Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/medical-use-cannabis.html. Accessed December 22, 2022.
- Health Canada. Authorized cannabis retailers in the provinces and territories; October 26, 2022. Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/provinces-territories.html. Accessed December 22, 2022
- Sandhu R, Saini G, Alvarez E. Using the 3I+E framework to assess provincial policy decisions for the sale of cannabis in Ontario, Saskatchewan and Quebec. Univ Tor J Public Health. 2021;2(1). doi:10.33137/utjph.v2i1.34726
- Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi:10.1093/intqhc/mzm042
- World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191. doi:10.1001/jama.2013.281053
- Watts S, McElroy M, Migicovsky Z, Maassen H, van Velzen R, Myles S. Cannabis labelling is associated with genetic variation in terpene synthase genes. Nat Plants. 2021;7(10):1330–1334. doi:10.1038/s41477-021-01003-y
- Ng JY, Quach H, Phillips MR, Busse JW. Surveying Canadian pain physicians’ attitudes and beliefs regarding medical Cannabis for chronic noncancer pain: a qualitative study. J Pain Res. 2022;15:3899–3910. doi:10.2147/JPR.S382589
- Reid M. A qualitative review of cannabis stigmas at the twilight of prohibition. J Cannabis Res. 2020;2(1):46. doi:10.1186/s42238-020-00056-8
- Corroon JM, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs – a cross-sectional study. J Pain Res. 2017;10(null):989–998. doi:10.2147/JPR.S134330
- Lucas P, Boyd S, Milloy MJ, Walsh Z. Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: results of a large prospective study. Pain Med. 2021;22(3):727–739. doi:10.1093/pm/pnaa396
- Piper BJ, DeKeuster RM, Beals ML, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31(5):569–575. doi:10.1177/0269881117699616
- Health Canada. Addiction to cannabis; March 2, 2018. Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/health-effects/addiction.html. Accessed March 29, 2023.
- Dolphin W, Newhart M. Cannabis use and mental health: paradoxes of medicalization. In: Harbusch M editor. Troubled Persons Industries: The Expansion of Psychiatric Categories Beyond Psychiatry. Springer International Publishing; 2022:245–287. doi:10.1007/978-3-030-83745-7_11